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Drug-eluting stent shows similar patency results as prosthetic bypass in patients 35 
with femoropopliteal occlusion in a randomized trial 36 
 37 
Abstract 38 
Introduction: Claudication and critical limb threatening ischemia (CLTI) are 39 
significant causes of mortality in the elderly. The gold standard of superficial femoral 40 
artery (SFA) revascularization is thus far considered to be the femoropopliteal bypass. 41 
The aim of this study was to compare mid-term patency between drug-eluting stents 42 
(DES) and prosthetic bypass grafts (BSX). Studies have reported comparable results 43 
for both methods. Materials and Methods: 46 patients with claudication or rest pain 44 
due to a 5-25 cm SFA-occlusion were randomized between DES and BSX. Follow-up 45 
was 24 months, and the primary outcome measure was overall patency. Secondary 46 
outcome measures were primary and primary assisted patency, change in ankle-47 
brachial index (ABI), as well as amputation-free survival. Results: 41 patients were 48 
eventually analyzed. 6 month secondary patency was 91 % (DES) vs. 83 % (BSX) 49 
(P=.450). The corresponding numbers at 12-months in the DES and BSX groups were 50 
74 % and 80 % (P= .750). At 24 months the respective numbers were 56 % and 71 % 51 
(P=.830). There were no statistically significant differences in primary or assisted 52 
primary patency at 1, 6, or 12 months. Conclusions: There were no demonstrable 53 
differences in patency rates or clinical outcomes such as ABI or major amputations 54 
between DES and BSX. Although underpowered, the results suggest non-inferiority 55 
of the DES compared to prosthetic bypass surgery. Trial registration: The trial was 56 
pre-registered at ClinicalTrials.org (NCT01450722) 57 
 58 
Introduction  59 
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Critical limb threatening ischemia (CLTI) due to atherosclerosis causes significant 60 
morbidity especially in the elderly, and, if untreated, leads to limb loss. 1 The 61 
incidence of CLTI is estimated at 500-1000/million annually. 2 The prevalence of its 62 
milder symptomatic manifestation, intermittent claudication among 40-44 year-old 63 
men is about .4 % and 3 % among 65-69 year-olds. 3 In asymptomatic peripheral 64 
artery disease or claudication, the ischemia relatively rarely deepens over time to 65 
threaten the vitality of the limb. 4 Although intermittent claudication has a benign 66 
prognosis and can often be treated conservatively, more severe forms with extensive 67 
arterial obstructions and symptoms that impair the quality of life significantly require 68 
revascularization. Open bypass surgery (BSX) is currently considered the gold 69 
standard for treating long obstructions in the superficial femoral artery (SFA). Up to 70 
81% two-year patency can be appreciated after bypass with a good quality saphenous 71 
vein. If synthetic graft is used, the long-term patency is somewhat lower, up to 67% 72 
according to a systematic review. 5 73 
 74 
Treatment of femoropopliteal occlusive disease has shifted dramatically towards 75 
endovascular methods during the last 10 years. 6 Despite this, superiority of 76 
endovascular treatment has not been definitively demonstrated. In 2010, the BASIL 77 
trial concluded that in patients with severe ischemia, femoropopliteal BSX with a vein 78 
graft was superior to primary angioplasty (BA), but that primary BA was superior to 79 
prosthetic BSX. 7 Furthermore, it was concluded that failed BA yielded worse 80 
outcomes for future ipsilateral BSX. This has been supported by subsequent studies. 8 81 
Comparison of stenting and prosthetic bypass grafting has yielded similar results at 4-82 
year follow-up in a RCT with 100 revascularizations and in a smaller, retrospective 83 
study. 9,10  84 
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 85 
Drug-eluting stents (DES) have proven their worth in coronary artery lesions and to 86 
some degree in femoral occlusions. 11 While early trials failed to show benefit from 87 
DES vs. bare metal stents 12,13, subsequent studies have shown improved event-free 88 
survival up to five years. 14 Paclitaxel is a mitotic inhibitor and antiproliferative 89 
agent.15 It is a widely used, effective agent in drug eluting stents to reduce restenosis 90 
in coronary circulation. 16 Paclitaxel binds specifically to the beta-tubulin subunit of 91 
microtubules and appears to antagonize the disassembly of this key cytoskeletal 92 
protein; this action results in accumulation of microtubule bundles and aberrant 93 
microtubule derived structures in the mitotic phase of the cell cycle. 17,18 The Zilver 94 
PTX (Cook Medical) paclitaxel-eluting stent is designed specifically for use in the 95 
SFA. It is a nitinol stent coated with paclitaxel only, without polymer or binder. 96 
 97 
This trial is a prospective, randomized, multicenter trial comparing outcomes for 98 
prosthetic above-knee (AK) bypass vs. the ZilverPTX drug eluting stent. Bypass with 99 
a synthetic graft, instead of autogenous vein, is used as a reference standard because 100 
of the difficulty to standardize the quality of available vein and because bypasses to 101 
the proximal popliteal artery with the different graft types give comparable results. 102 
The trial was investigator initiated, and did not receive funding from the industry. 103 
 104 
Materials and Methods 105 
Patients were randomized at 6 hospitals in Finland (Helsinki, Oulu, Turku and Kuopio 106 
university hospitals and the central hospitals in Lahti and Joensuu). Patients were 107 
included between 2011 and 2014, follow-up ended in 2016.  Patients presented with 108 
rest pain or severe claudication (Rutherford class II-IV), patients with wounds or 109 
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tissue loss were excluded. 5-25 cm SFA-lesions were eligible for inclusion. The 110 
lesions were diagnosed and measured using magnetic resonance angiography (MRA) 111 
or computed tomography angiography (CTA). Concomitant inflow or outflow 112 
procedures were not allowed. All patients provided written informed consent. 113 
Inclusion and exclusion criteria are listed in table 1.  Patients were randomized to 114 
BA+DES or prosthetic AK femoropopliteal bypass. 2:1 (DES:BSX) block 115 
randomization was performed at the ward or outpatient clinic following eligibility and 116 
signed informed consent. 117 
 118 
Bypass Surgery 119 
Bypass surgery was performed under general anesthesia or spinal blockade from 120 
incisions to the groin and proximal popliteal artery. A 6 mm heparin-bonded 121 
polytetrafluoroethylene (PTFE) graft was used. The graft was tunneled anatomically 122 
or subcutaneously depending on surgeon´s preference. Procedures were performed 123 
under systemic heparinization with an activated clotting time (ACT) between 200 and 124 
300 seconds. 125 
 126 
Balloon Angioplasty and Drug-Eluting Stent 127 
Access was obtained from the ipsilateral or contralateral common femoral artery. The 128 
occlusion was recanalized and crossed intraluminally or subintimally prior to 129 
predilatation and stent deployment. The stent was post-dilated according to 130 
instructions-for-use. Patients received 5000 IU systemic heparin during the procedure. 131 
 132 
Follow-up and outcome measures 133 
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Follow-up was 24 months and the primary outcome measure was overall stent or graft 134 
patency. Secondary outcome measures were primary and assisted patency, change in 135 
ankle-brachial index (ABI), as well as amputation-free survival. Follow-up was 136 
performed by clinical evaluation for symptoms and by duplex ultrasound to assess 137 
patency at 1, 6, 12, and 24 months postoperatively.  138 
 139 
Antithrombotic regime 140 
Postoperatively, all patients except those on warfarin were started on life-long ASA 141 
treatment in both treatment groups. Patients in the DES group were on dual 142 
antiplatelet therapy (ASA 100 mg + clopidogrel 75 mg daily) for at least three months 143 
postoperatively. DES-patients on warfarin were started on low-dose (50 mg) ASA for 144 
the same period. Dual antiplatelet therapy was not prescribed after bypass surgery. 145 
 146 
Randomization 147 
Block randomization (2:1) was performed by concealed envelope by the research 148 
nurse at the University of Kuopio. Due to the nature of the study, neither subjects, 149 
providers nor outcomes assessors were blinded. 150 
 151 
Statistical Analysis 152 
Statistical analysis was performed using SPSS v. 22 (IBM, Armonk, VA, USA) 153 
Continuous variables are expressed as means and range or medians and interquartile 154 
range (IQR) and dichotomous variables as percentages. Continuous variables were 155 
compared using Mann-Whitney test and dichotomous variables using Chi-square.  156 
Patency rates were analyzed with Log-rank testing. 157 
 158 
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The study was approved by the ethical boards of Kuopio University Hospital and 159 
Helsinki University Hospital and the study design was declared and preregistered at 160 
ClinicalTrials.org (NCT01450722). 161 
 162 
Results 163 
46 patients were randomized. Baseline characteristics are described in table 2. 5 164 
patients were excluded due to immediate technical failure, i.e. unsuccessful 165 
recanalization. These were salvaged by distal and/or venous bypass, and thus not 166 
eligible for intention-to-treat analysis. There were no deaths or major amputations in 167 
either group during 12-month follow-up, 1 patient in the stent group died at 24 168 
months from procedure due to unrelated disease. The number of patients lost to 169 
follow-up at 6, 12, and 24 months was 0 (0.0 %), 6 (14.2 %) and 11 (26.2 %), 170 
respectively. In the DES-group, the median number of stents was 2 (range 1-4) with a 171 
median diameter of 6 mm. 172 
41 patients were eventually analyzed. 6 month primary patency was 82.6 % DES) vs. 173 
72.2 % (BSX) (P=.447) and secondary 91 % vs. 83 % (P=.450). The 12-month 174 
secondary patency in the DES and BSX groups was 74 % compared to 80 % (P= 175 
.750). There were no statistically significant differences in primary, assisted primary, 176 
or secondary patency at 1, 6, 12, or 24 months (table 3, fig 1-2).  The median ABI 177 
rose from .54 to .93 in the DES-group and from .65 to 1.02 in the BSX-group after the 178 
procedures and there were no significant differences between the groups at the 179 
baseline nor during the follow-up (Table 4). Relative risk for stenting at 1 year was 180 
.96 (P= .893, any endpoint). 181 
 182 
Discussion 183 
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In the current trial, no significant differences between femoropopliteal AK bypass 184 
with PTFE-prosthesis and endovascular recanalization and stenting with Zilver-PTX 185 
stenting could be demonstrated. At 6 months, the primary and secondary patencies 186 
were slightly, but not significantly, higher in the stent group compared to bypass, but 187 
this difference disappeared during the next six months. At 12 months the respective 188 
rates were surprisingly similar: 63.2 % vs. 66.7 % and 74 % vs. 80 %. Indeed, at two 189 
years, the patency rate was better in the BSX group (56 % vs. 71 %, P=.397) but at 190 
this stage the number-at-risk is substantially lower than at the earlier follow-ups.    191 
 192 
For the time being, open femoropopliteal BSX is a first-hand option in many centers 193 
worldwide. Use of prosthetic grafts for AK bypasses remains popular due to many 194 
surgeons’ preference to save the saphenous veins for possible future below-knee or 195 
distal bypasses and speed of the procedure. The Zilver PTX DES is designed 196 
specifically for femoropopliteal locations. A prospective, randomized trial reported 197 
significantly better 24-month event-free survival among patient receiving a DES than 198 
among those treated with PTA alone (86.6% vs. 77.6%, P< .01). 19 Primary patency at 199 
24 months of the DES group was 74.8% vs. 32.4% for the PTA group. Patency rates 200 
at 5 years further favored the Zilver PTX. 14 The Zilver PTX trials have shown 201 
patency rates in the 80 %-range at 12 months, which are comparable to our results. 202 
The Scandinavian Thrupass study demonstrated a clear benefit in favor of bypass 203 
surgery vs. the Gore Thrupass endoluminal PTFE. 20 This trial showed a remarkable 204 
95 % 1-year patency in the bypass treatment group, whereas the corresponding 205 
number was only 48 % for the thrupass group. In 2007, Kedora et al demonstrated 206 
comparable 1-year outcomes between the Viabahn covered stent (CS) and prosthetic 207 
AK femoropopliteal bypass. 21 This study included 100 limbs in a prospective setting.  208 
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In this study, 6 and 12-month patency rates were 82 % (BSX) vs. 81.8 % (CS) and 209 
73.5 % vs. 74.2 %, respectively. In our study the patency rates were somewhat higher 210 
at 6 months and lower at 12 months, but still in comparable figures. The study by 211 
Kedora et al has been criticized for including TASC A lesions.  212 
 213 
It should be noted that 5 cases (5/27, 18.5 %) were excluded from the DES group due 214 
to failed recanalization, whereas the primary technical success rate in the BSX group 215 
was 100 %.  In one case the attempted recanalization resulted in severe distal 216 
dissection and acute ischemia, which eventually could be salvaged with a distal 217 
bypass. We did not report the results for patients with technical failures, but no 218 
statistically significant difference was seen in a sensitivity analysis including these 219 
patients. Furthermore, 1 case in the DES group received a bailout covered stent after 220 
perforation and hemorrhage. This did not compromise patency, as the DES in 221 
question was patent at 2 years.  222 
 223 
In this trial, there was a significant difference between the groups in time from 224 
diagnosis to treatment. The time from CT or MR angiography to treatment was 60 225 
days in the DES group and 125 days in the BSX group (P<.01). This is likely due to 226 
hospital logistics and the more rigorous medical work-up prior to bypass surgery. 227 
There was no evidence that this delay would have resulted in clinical deterioration in 228 
the BSX patients prior to surgery. 229 
 230 
This trial is limited by the small sample size, and consequently there is a marked risk 231 
for type II error in the patency rates. The primary reason for the slow inclusion and 232 
randomization rate was the quickly somewhat ageing hypothesis and clinically 233 
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problematic setting for prosthetic bypass surgery; few surgeons would end up 234 
including the shorter SFA-lesions into this trial design, as these are routinely treated 235 
with less invasive endovascular procedures, or, indeed, venous bypass grafting. This 236 
is overall seen in decreasing rates of open AK bypass surgery and quite the opposite 237 
in successful endovascular femoropopliteal revascularizations. 238 
 239 
Despite its limitations, we think our paper gives valuable information on the outcome 240 
after these two procedures and it seems that the DES is not inferior to prosthetic AK 241 
bypass in patients with SFA occlusion 25 cm or less. This is the only prospective trial 242 
to date comparing DES with bypass surgery, and the results do indicate that drug-243 
eluting stents are comparable to prosthetic grafts with regard to patency. Another 244 
strength of the trial is comprehensive follow-up at 6 months, and acceptable follow-up 245 
rates up to 24 months. In anticipation of larger trials, the results from this trial loosely 246 
favor endovascular revascularization and use of DES for SFA lesions if no vein is 247 
available for grafting.   248 
 249 
Conclusions 250 
This is the first randomized trial comparing the DES to prosthetic bypass in above 251 
knee femoropopliteal occlusion. At 12 and 24 months after the procedure there was no 252 
statistically significant difference in primary patency, assisted primary patency or 253 
secondary patency between the groups. Although underpowered, our study suggests 254 
non-inferiority of the DES compared to PTFE-bypass in this patient group. Larger 255 
studies are needed for more definitive conclusions. 256 
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Inclusion Criteria: Exclusion Criteria 
Rutherford class II-IV Previous treatment for same lesion 
5-25 cm SFA occlusion Indication for infrapopliteal treatment 
Eligible for operative treatment Iodine allergy 
At least 1 vessel crural runoff Patients undergoing hemodialysis 
Written informed consent Pregnancy 
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DES 
(n=23) 
BSX 
(n=18) P-value 
Male sex 17 12 .613 
Age 68 48-88 67 50-84 .398 
T1 Diabetes 6 26.1 4 22.2 .775 
T2 Diabetes 3 13.0 2 11.1 .650 
Smoking 9 39.1 6 33.3 .702 
Ex-smoker 9 39.1 5 27.8 .230 
TIA 2 8.7 2 11.1 .796 
Stroke 3 13.0 2 11.1 .851 
Coronary disease 6 26.1 5 27.8 .903 
Prior AMI 1 4.3 3 16.7 .187 
Dyslipidemia 13 56.5 15 83.3 .067 
Chronic heart disease 2 8.7 2 11.1 .796 
Hypertension 15 65.2 15 83.3 .194 
Pulmonary 1 4.5 1 5.6 .884 
ASA 21 91.3 14 77.8 .224 
Clopidogrel 1 4.3 4 22.2 .083 
Warfarin 3 13.0 2 11.1 .851 
Other 2 8.6 1 5.6 .653 
Statin therapy 12 52.2 14 77.8 .051 
ACE/AT2-blockade 9 39.1 9 50.0 .656 
Ankle Brachial Index 0.54 0-0.82 0.65 0.47-0.99 .120 
SFA occlusion length 13.2 5.0-25.0 (IQR 12.3) 11.3 5.0-19.6 (IQR 7.9) .424 
Rutherford classification 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1 4 17.4 3 16.7 .359 
2 7 30.4 8 44.4 
3 6 26.1 6 33.3 
4 6 26.1 1 5.6 
Crural runoff* 
3 8 34.8 5 27.8 .782 
2 8 34.8 4 22.2 
1 7 30.4 2 11.1 
0 0 0 1 5.6 
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DES BSX P-value (log-rank) 
1 m  
Primary patency (%) 87.0 88.9 .872 
Assisted primary patency (%) 87.0 88.9 .872 
Secondary patency (%) 87.0 94.4 .454 
6 m 
Primary patency (%) 87.0 72.2 .447 
Assisted primary patency (%) 91.3 77.8 .247 
Secondary patency (%) 91.3 83.3 .450 
12 m 
Primary patency (%) 63.2 66.7 .931 
Assisted primary patency (%) 68.4 73.3 .840 
Secondary patency (%) 73.7 80.0 .750 
24 m 
Secondary patency (%) 56.3 71.4 .830 
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ABI DES BSX P-value 
mean range mean range 
post.op. .93 .63-1.38 1.02 .76-1.42 .220 
1 m .99 .39-1.85 .94 .78-1.09 .620 
6 m .93 .59-2.00 .80 .31-1.12 .650 
12 m .86 .73-.98 .85 .54-1.05 .791 
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